TaiMed Biologics Inc. (TAIMED BIOLOGICS INC.) aksje

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.